Skip to contentS
Spyre Therapeutics, Inc.
S
SYRESpyre Therapeutics, Inc. Q2 2020 · 10-Q
Revenue—
Net Income-$21.42M-$21.42MN/M vs Q2 2019 EPS Diluted-$0.40-$0.40N/M vs Q2 2019 Operating Income-$21,560,000N/M Operating Cash Flowderived-$19,413,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spyre Therapeutics, Inc. · CIK 1636282 · Engraved from SEC EDGAR
Free Cash Flowderived-$20,738,000N/M ended Jun 30, 2020 · filed Aug 10, 2020 · 41 d after period end